Anna Christoforidou

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients

Eirini Katodritou, Evangelos Terpos, Argiris Symeonidis et al. · American Journal of Hematology · 2014 · 67 citations · Full text

Prognostic Factors, Surgical Oncology, Adjuvant Chemotherapy +16

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies

Flora Zagouri, Efstathios Kastritis, Athanasios Zomas et al. · European Journal Of Haematology · 2017 · 46 citations

Expression of the Tpl2/Cot oncogene in human T-cell neoplasias.

Anna Christoforidou, Helen Α. Papadaki, Andrew N. Margioris et al. · Molecular Cancer · 2004 · 44 citations · Full text

Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with 166Holmium-DOTMP as Conditioning Regimen for Autologous Stem Cell Transplant for Patients with Multiple Myeloma. Impact on Transplant Outcomes

Anna Christoforidou, Rima M. Saliba, Patricia Williams et al. · Biology of Blood and Marrow Transplantation · 2007 · 29 citations · Full text

Treatment Verification, High-dose Melphalan, Hematological Malignancy +22

Alendronate reduces serum TNF? and IL-1?, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis

Helen Α. Papadaki, Christos Tsatsanis, Anna Christoforidou et al. · Journal of Bone and Mineral Metabolism · 2004 · 28 citations

Inflammation, Bone Disease, Bone Health +9